Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-07-24

Clinical Trial Update: Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED) [Phase 2]

View source ↗

Summary

A Phase 2 trial of MK0677 for Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MK0677 (ibutamoren)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED